Storys zum Thema Impfung

NanoPass; Emergex

NanoPass's intradermal delivery platform used in Emergex's next generation COVID-19 vaccination study

Nes Ziona, Israel (ots/PRNewswire) - Intradermal COVID-19 vaccination studies are emerging in a global effort to use available doses more effectively by harnessing skin immunity to reduce the dosage required for effective vaccination, as well as to improve the immunogenicity of weaker vaccines. Additionally, there ...

News Direct

ALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS

R-Biopharm AG

2

R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation

Schweizerischer Nationalfonds / Fonds national suisse

Innovative research into new vaccines

Bern (ots) - Projects taking part in the National Research Programme "Covid-19" (NRP 78) of the Swiss National Science Foundation (SNSF) are pursuing highly promising approaches in a drive to develop new vaccines. Three research groups have adopted interesting approaches to the highly topical issue of vaccines. The team led by Steve Pascolo is investigating ways of improving functionality and stability of mRNA vaccines, ...

Shycocan

TNO research shows effectiveness of corona cannon

Rijswijk, Netherlands (ots/PRNewswire) - Addition due to incomplete information in the press release as sent on 4 June 2021 Analyses carried out by TNO in a BSL-3 laboratory cabinet showed that the corona gun had achieved a 94.9% reduction in the Covid -19 virus after 15 minutes. In the laboratory set-up, the (live) virus was located on stainless steel plates at 85 cm from the device. Earlier, the Dutch scientific ...

Debiopharm International SA

DEBIOPHARM COLLABORATES WITH INNOCENTIVE FOR THE LAUNCH OF A GLOBAL CHALLENGE TO DEVELOP A SINGLE-DOSE mRNA COVID-19 VACCINE

Lausanne, Switzerland (ots) - - Currently approved COVID-19 vaccines based on messenger RNA (mRNA) technology require two injections, given several weeks apart, for optimal protection against the virus - Debiopharm has launched a vaccine innovation challenge to a pool of international “problem Solvers” within ...

Intravacc

Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine

Bilthoven, Netherlands (ots/PRNewswire) - - Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2 - Intranasal vaccine administration has significant advantages over injectables - OMV technology is a powerful vaccine platform for future pandemics Intravacc, a global leader in translational research and development of viral and bacterial ...

Fürstentum Liechtenstein

Promising results from Liechtenstein study on early detection of Covid-19 / Sensory bracelet indicates infection two days before appearance of first symptoms

Vaduz (ots) - A scientific consortium led by Liechtenstein scientists and entrepreneurs Lorenz Risch and Martin Risch launched the prospective "COVI-GAPP study", involving more than 1100 subjects from the Principality of Liechtenstein, in April 2020. The aim was to show whether a sensory bracelet, already used ...

DG-Nika AG

2

First pocket inhaler for Covid-19 and other viral mutations

Merck Healthcare Germany GmbH

New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines

Darmstadt, Germany (ots/PRNewswire) - MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine ...

FDI World Dental Federation

New FDI World Dental Federation global survey reveals that two-thirds of countries are not allowing dentists to administer COVID-19 vaccines

Geneva, Switzerland (ots) - Survey also shows that half of the responding countries have agreed to include dentists in their priority vaccination groups FDI World Dental Federation today called for more countries to enable dentists to administer COVID-19 vaccines after a survey of its members revealed the small ...

Swiss Rockets AG

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

MSD Merck Sharp & Dohme AG

MSD (Merck Sharp & Dohme AG) Switzerland appoints Ans Heirman, Ph.D. as the new Managing Director of MSD Switzerland, effective September 1st, 2020

Viroclinics Biosciences

Davide Molho, DVM Joins Viroclinics Biosciences as Chief Executive Officer

Rotterdam, Netherlands (ots/PRNewswire) - Viroclinics Biosciences B.V. ("Viroclinics") today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company's new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company's CEO since 2011. This transition is part of a planned succession strategy. Dr. ...

Schweizerischer Nationalfonds / Fonds national suisse

Meeting challenges through basic research

Bern (ots) - Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception. A special call and a ...

IgNova GmbH

IgNova files patent application on antibody against COVID-19

Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...

Zhejiang Hisun Pharmaceutical Co. Ltd

Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiravir

Taizhou, China (ots/PRNewswire) - Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly ...

Seqirus

First Adjuvanted Quadrivalent Influenza Vaccine by Seqirus Receives EU Approval

Maidenhead, England (ots/PRNewswire) - The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in several European countries. aTIV has ...

Neovii Pharmaceuticals AG

NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine

Rapperswil, Switzerland and Tel Aviv, Israel (ots/PRNewswire) - The epitope-based vaccine will target the most vulnerable part of the viral spike protein Ramot , Tel Aviv University's technology transfer company, and Neovii , a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license ...

Neovii Pharmaceuticals AG

NEOVII to Develop a Novel Vaccine for COVID-19 in an Exclusive Partnership With Tel Aviv University

Rapperswil, Switzerland (ots/PRNewswire) - Neovii, the Swiss-based biopharmaceutical company and a member of Israeli-based Neopharm Group, has signed a research and license agreement with Tel Aviv University's (TAU) RAMOT, its technology transfer company, to work in collaboration with a team led by Professor ...

MSD Merck Sharp & Dohme AG

MSD in Switzerland launches new gender-neutral parental leave policy effective February 1st, 2020

Lucerne (ots) - Following its nomination for an eight time in a row as Top Employer Switzerland, MSD (Merck Sharp & Dohme AG) is delighted to announce the introduction of a new gender-neutral parental leave policy to all its employees within ...

MSD Merck Sharp & Dohme AG

MSD Expands Operations in Switzerland

Lucerne (ots) - - Company will open a new location in Zurich, focused on accelerating research, data and commercialization of our medicines and vaccines - Lucerne will remain the center of MSD's presence in Switzerland MSD (Merck Sharp & Dohme AG) today announced that it will establish a new office in Zurich, Switzerland, aimed at accelerating the ...

AJ Vaccines

AJ Vaccines Will Contribute to the Global Polio Eradication With its Innovative Polio Vaccine

The new adjuvanted polio vaccine has been approved by the Danish Medicines Agency, and the WHO prequalification is expected by the end of 2019, enabling initial delivery of up to 100 million doses globally via UN agencies in 2020-2024 Copenhagen, Denmark (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY AJ Vaccines today announced that its adjuvanted IPV vaccine has ...